{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:31:31Z","timestamp":1776720691091,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clml.2020.01.010","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:36:31Z","timestamp":1580124991000},"page":"407-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation"],"prefix":"10.1016","volume":"20","author":[{"given":"Liana","family":"Nikolaenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran N.","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.01.010_bib1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.010_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/10428194.2016.1228926","article-title":"Treatment options for relapse after autograft in multiple myeloma\u2014report from an EBMT educational meeting","volume":"58","author":"Garderet","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.010_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.010_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0037-1963(01)90016-2","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma","volume":"38","author":"Bensinger","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2020.01.010_bib6","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib7","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bmt.2017.183","article-title":"Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients","volume":"52","author":"Montefusco","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2017.10.014","article-title":"Long-term follow-up of a donor versus no-donor comparison in patients with multiple myeloma in first relapse after failing autologous transplantation","volume":"24","author":"Patriarca","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.2001.03153.x","article-title":"Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study","volume":"115","author":"Martino","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.01.010_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","article-title":"Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning","volume":"121","author":"Einsele","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.01.010_bib12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bmt.2017.141","article-title":"In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review","volume":"52","author":"Oostvogels","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.bbmt.2018.04.018","article-title":"Long-term results of prophylactic donor lymphocyte infusions for patients with multiple myeloma after allogeneic stem cell transplantation","volume":"24","author":"Groger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clml.2020.01.010_bib16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.01.010_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib18","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.01.010_bib19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/bmt.2015.48","article-title":"The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs","volume":"50","author":"Franssen","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1701980","article-title":"Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation","volume":"24","author":"Libura","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib21","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.010_bib22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A\u00a0comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.010_bib24","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib25","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A\u00a0prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib26","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","article-title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"107","author":"van de Donk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib27","first-page":"759","article-title":"Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT","volume":"17","author":"Samson","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib28","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bmt.1703292","article-title":"Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation","volume":"28","author":"Biagi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib30","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kroger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib32","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Chanan-Khan","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.01.010_bib33","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.010_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ph10020040","article-title":"Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics","volume":"10","author":"Chhabra","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clml.2020.01.010_bib35","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.010_bib36","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.010_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2020.01.010_bib38","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3109\/10428194.2012.656635","article-title":"Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant","volume":"53","author":"Beitinjaneh","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.010_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bmt.1705393","article-title":"Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"37","author":"van de Donk","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bmt.1704670","article-title":"Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.010_bib41","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib42","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.01.010_bib43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.010_bib44","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.01.010_bib45","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nbt0216-126","article-title":"FDA approves three different multiple myeloma drugs in one month","volume":"34","author":"Ratner","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clml.2020.01.010_bib46","first-page":"E1286","article-title":"Daratumumab is an effective and safe salvage therapy in relapsed\/refractory patients with multiple myeloma after allogeneic stem cell transplantation","volume":"181062","author":"Klyuchnikov","year":"2017","journal-title":"EHA Library"},{"key":"10.1016\/j.clml.2020.01.010_bib47","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.010_bib48","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.010_bib49","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.010_bib50","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features","volume":"22","author":"Rasche","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:08Z","timestamp":1761870848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2152265020300471"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}